A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (TURANDOT II)
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2019
At a glance
- Drugs SHP 647 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Acronyms TURANDOT-II
- Sponsors Pfizer; Shire
- 24 Oct 2018 Results assessing long-term safety and tolerability of SHP647 presented at the 26th United European Gastroenterology Week.
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
- 21 Dec 2017 Status changed from active, no longer recruiting to completed.